Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
2.54 ^USD	+11.89%		+22.71%	-4.87%

May. 02	Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	CI
Apr. 30	Top Midday Gainers	MT

Cyclacel Pharmaceuticals, Inc. Appoints Robert J. Spiegel to the Board of Directors

November 12, 2018 at 04:05 pm EST

Cyclacel Pharmaceuticals, Inc. Appointed Robert J. Spiegel to the Board of Directors. Dr. Spiegel brings over 30 years of R&D and operational experience in the biopharmaceutical industry as well as advisory experience to venture capital and private equity funds.

Latest news about Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	May. 01	CI
Top Midday Gainers	Apr. 30	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	Apr. 30	MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8.000001 million in funding	Apr. 29	CI
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	Apr. 29	DJ
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	Apr. 01	CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	Mar. 19
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	Mar. 19	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals, Inc. Announces Board Changes	Jan. 30	CI
Cyclacel Pharmaceuticals, Inc. Announces Executive Changes	Jan. 30	CI
Top Premarket Gainers	Jan. 08	MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $0.026374 million in funding	Dec. 21	CI
North American Morning Briefing : S&P 500 Futures -2-	Dec. 20	DJ
Brookline Capital Downgrades Cyclacel Pharmaceuticals to Hold From Buy	Dec. 19	MT
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions	Dec. 18	CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Earnings Flash (CYCC) CYCLACEL Reports Q3 Revenue $16,000	Nov. 13	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 13	CI
Cyclacel Pharmaceuticals Files $100 Million Mixed Shelf	23-09-05	MT
Transcript : Cyclacel Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Earnings Flash (CYCC) CYCLACEL Posts Q2 Revenue $373,000	23-08-09	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-09	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

Chart Cyclacel Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

Sector

Biotechnology & Medical Research

Calendar

04:05pm - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.54 USD

Average target price

11 USD

Spread / Average Target

+333.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYCLACEL PHARMACEUTICALS, INC.	-4.87%	3.72M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-2.68%	21.93B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-5.61%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-10.09%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.45B

Bio Therapeutic Drugs